Business Description
Kodiak Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US50015M1099
Compare
Compare
Traded in other countries / regions
KOD.USAK27.GermanyKOD.Mexico IPO Date
2020-09-14Description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.69 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.7 | |||||
| 3-Year EPS without NRI Growth Rate | -19.5 | |||||
| 3-Year FCF Growth Rate | -23.6 | |||||
| 3-Year Book Growth Rate | -33 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.42 | |||||
| Quick Ratio | 8.42 | |||||
| Cash Ratio | 8.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 2.39 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -79.23 | |||||
| ROA % | -42.85 | |||||
| ROIC % | -105.65 | |||||
| ROC (Joel Greenblatt) % | -113.76 | |||||
| ROCE % | -46.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.89 | |||||
| Price-to-Tangible-Book | 1.89 | |||||
| EV-to-EBIT | -1.18 | |||||
| EV-to-Forward-EBIT | -1.17 | |||||
| EV-to-EBITDA | -1.37 | |||||
| EV-to-Forward-EBITDA | -1.28 | |||||
| EV-to-FCF | -1.54 | |||||
| Price-to-Net-Current-Asset-Value | 23.01 | |||||
| Price-to-Net-Cash | 33.33 | |||||
| Earnings Yield (Greenblatt) % | -84.75 | |||||
| FCF Yield % | -41.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kodiak Sciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -65.287 | ||
| Beta | -0.58 | ||
| Volatility % | 31.58 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 2.004085 | ||
| 20-Day SMA (MXN) | 137.918 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 110 - 160.76 | ||
| Shares Outstanding (Mil) | 52.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kodiak Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kodiak Sciences Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kodiak Sciences Inc Frequently Asked Questions
What is Kodiak Sciences Inc(MEX:KOD)'s stock price today?
The current price of MEX:KOD is MXN110.00. The 52 week high of MEX:KOD is MXN160.76 and 52 week low is MXN110.00.
When is next earnings date of Kodiak Sciences Inc(MEX:KOD)?
The next earnings date of Kodiak Sciences Inc(MEX:KOD) is 2025-03-28 Est..
Does Kodiak Sciences Inc(MEX:KOD) pay dividends? If so, how much?
Kodiak Sciences Inc(MEX:KOD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers